Conditions
Respiratory Syncytial Virus
6 articles published between November 21, 2025 and October 14, 2026.
Covered in Children & Family Health and Science.
THE DRUG DOCKETIn a 180-infant phase 1/2 trial, a live-attenuated intranasal RSV vaccine raised neutralising antibodies in two-thirds or more of RSV-naive babies but barely budged those already exposed. Sanofi funded the study.
3 min read
WHAT THE STUDY ACTUALLY SAYSIn Scottish hospital data, RSV was recorded about 2.3 times as often as human metapneumovirus, but patients admitted with either virus were similarly ill — and the analysis was funded by a maker of RSV products.
3 min read
WHAT THE STUDY ACTUALLY SAYSA government-funded test-negative study put effectiveness at 86% against emergency visits and 88% against intensive care, though the smallest subgroups carried wide confidence intervals.
4 min read
WHAT THE STUDY ACTUALLY SAYSA test-negative study across seven paediatric hospitals in Ontario and Quebec, run after a publicly funded rollout, estimated 78% effectiveness against laboratory-confirmed RSV and 97% against intensive-care admission.
4 min read
WHAT THE STUDY ACTUALLY SAYSThe SMART trial tested clesrovimab against palivizumab in premature and heart- and lung-affected infants. It was built to show safety, not to prove one prevents more RSV than the other.
3 min read
WHAT THE STUDY ACTUALLY SAYSA Buenos Aires surveillance cohort estimates 80.8% effectiveness against RSV hospitalisation in infants under three months — close to what the licensing trial found, in a real programme.
3 min read
This page indexes this newspaper’s reporting on Respiratory Syncytial Virus. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.